Need of guidance in disabling and chronic migraine identification in the primary care setting, results from the european MyLife anamnesis survey

Angel L. Guerrero1,2,3*, Andrea Negro4,5, Philippe Ryvlin6, Kirill Skorobogatykh7, Rainel Sanchez-De La Rosa8, Heike Israel-Willner9, Christina Sundal10,11 and E. Anne MacGregor12,13

Abstract

**Background:** Migraine affects 80.8 million people in Western Europe and is the first cause of disability among people between ages 15 and 49 worldwide. Despite being a highly prevalent and disabling condition, migraine remains under-diagnosed and poorly managed.

**Methods:** An international, online survey was conducted among 201 general practitioners (GPs) from 5 European countries (France, Germany, Italy, Spain and the UK) who are experienced in the management of headache disorders.

**Results:** The majority of GPs (82%) did not refer patients with chronic migraine (CM) to migraine specialists. Among those patients, the participants estimated that around 55% received preventive medication. Some differences between countries were observed regarding referral rate and prescription of preventive treatment. Most GPs (87%) reported a lack of training or the need to be updated on CM management. Accordingly, 95% of GPs considered that a migraine anamnesis guide could be of use. Overall, more than 95% of GPs favoured the use of a patient diary, a validated diagnostic tool and a validated scale to assess impact of migraine on patients’ daily life. Similarly, 96% of the GPs considered that the inclusion of warning features (red flags) in an anamnesis guide would be useful and 90% favoured inclusion of referral recommendations.

**Conclusions:** The results from this survey indicate that more education on diagnosis and management of CM is needed in primary care. Better knowledge on the recognition and management of migraine in primary care would improve both prognosis and diagnosis and reduce impact of migraine on patients’ lives, healthcare utilization and societal burden.

**Keywords:** Headache disorders, Chronic migraine, Anamnesis, Diagnosis, Management, Primary care, Support, Red-flags, Referral

*Correspondence: gueneurol@gmail.com
1 Neurology Department, Headache Unit, Hospital ClinicoUniversitario, Valladolid, Spain
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Headache disorders and in particular migraine, are one of the most prevalent and disabling diseases worldwide [1, 2]. Migraine is the leading cause of disability among men and women between ages 15 and 49, accounting for 8.2% of total years lived with disability worldwide [1–3]. In Western Europe, 80.8 million people suffer from migraine according to the latest Global Burden of Disease study [1]. Migraine has an enormous impact on patients’ private, social and professional lives and causes substantial societal burden [3–5].

Approximately 2.5% of people with episodic migraine (EM) develop chronic migraine (CM) each year [6], which is significantly more disabling than EM [4, 7]. In CM, attacks become more frequent and their clear periodicity is lost. CM is defined as headache occurring 15 or more days per month for more than 3 months, of which, at least 8 days per month, have features of migraine headache [8]. The prevalence estimates of CM range between 1 and 2% worldwide [6, 9].

Accurate diagnosis of headache disorders can be challenging for non-specialists clinicians [10]. Despite being one of the most common reasons for visits to primary care [11], formal training on recognition and management of headache disorders for general practitioners (GPs) is limited [12]. Diagnosis of the three most prevalent headache disorders - tension type headache (TTH), migraine and medication overuse headache (MOH) - is based on medical history or anamnesis [13, 14]. However, when headache presents, patients and physicians are concerned about possible serious underlying causes [14]. Diagnostic uncertainty favours unnecessary ancillary testing (i.e. imaging), is uncomfortable for the patient, increases healthcare costs and delays timely treatment [14].

Both diagnosis and management of patients with migraine are often suboptimal [15, 16]. The European Headache Federation (EHF) recommends that both EM and CM are diagnosed in primary care, but suggests that CM might require specialist management [13]. Several studies have reported that up to 70% of patients with migraine are not aware of their disease and/or have not been properly diagnosed [15, 17]. Even when accurately diagnosed, patients are often undertreated and not satisfied with their treatment [15, 16, 18, 19]. Failure of acute treatment in patients with EM has been linked to higher risk of medication overuse, which may cause MOH and is a risk factor for CM [20].

The present survey has been conducted among GPs with experience in headache disorders from 5 European countries (France, Germany, Italy, Spain and the UK). The aims of this study were to assess current management of CM in primary care and to evaluate the need by non-migraine specialists for guidance to identify and manage disabling and CM.

Methods

Study design, participants and survey

My-LIFE anamnesis project was an international, online survey to GPs who are experienced in management of headache disorders, with regard to their current practice, perceived needs and important topics for migraine anamnesis in primary care.

The questionnaire for the online survey was designed by a pan-European Steering Committee with 7 European experts on migraine management. After a literature search, an initial document that included the most important points for a migraine anamnesis guide was developed. This document was used in six simulated consultations with six different healthcare practitioners (HCP) and six different patients in June 2019, three in Barcelona (Spain) and three in London (UK). Simulated consultations were used to gather insights regarding the need and potential usefulness of a migraine anamnesis tool to guide non-specialists in the identification of CM, and to gain information from neurologists, GPs and patients for the development of the survey questionnaire. The Steering Committee developed the survey questionnaire, which consisted of three parts, with 32 items regarding participants’ clinical experience, current clinical practice with regard to patients with disabling and CM, and perceptions on their need of support for the identification of patients with CM and the important topics for a migraine anamnesis guide (Additional file 1). The questionnaire was written in English and translated into local languages (French, German, Italian, and Spanish). It was administered to 201 GPs fulfilling the inclusion criteria between 14th January 2020 and 28th January 2020 through an online platform that ensured data anonymity and confidentiality.

The participants were randomly selected by a fieldwork company taking into account their geographical location to ensure a similar number of participants from each of the five countries. Experience in the management of headache disorders was defined as: (1) having ≥2 years of experience in general practice; (2) seeing ≥5 patients with headache disorders per week; (3) usually proceeding with the anamnesis of their patients with headache disorders, and (4) currently having ≥1 patient suffering from episodic and/or CM under treatment.

Ethics Committee approval was not applicable in this survey because its objective was to understand chronic migraine patients’ management in the primary care setting according to participants recall. There was no need to collect any type of patient data or information, hence the approval of an Ethics Committee or patient informed consent was not necessary.
consent was not required. All survey participants gave their written consent.

Data analysis
Number of respondents was expressed as frequencies, percentages, means, standard deviations (SD) and range (min–max). Comparative analyses were carried out with Student’s t-tests, ANOVA or Chi-square tests. Data were analysed with SPSS version 22, and \( p < 0.05 \) was considered statistically significant. In this study all analyses are simply exploratory so no adjustment for multiple testing was conducted.

Results
Simulated consultations
Four simulated consultations were carried out by neurologists, and two by GPs. Neurologists felt that an anamnesis guide to identify and manage CM was not needed for migraine specialists but could be useful for GPs. GPs considered that inclusion of red flags for secondary headaches was helpful. Regarding patients’ perspective, patients felt that the use of a diary was very useful as it helped them to better articulate the migraine experience and its frequency and impact on daily life.

Online survey
Participants’ profile
A total of 201 GPs with experience on the management of headache disorders from France, Germany, Italy, Spain and the UK participated in the online survey. On average, participants had 24 years of clinical practice experience and saw 202 patients per week, of whom 12% suffered from headache disorders, of which 38% were diagnosed of migraine. Among migraine patients 66% presented EM and 34% CM. Detailed information about how identification, diagnosis and follow-up of patients with episodic migraine and CM are conducted by the GPs in this survey is reported separately [21].

Management of patients with disabling and CM
Up to 82% of GPs continued to manage patients after they were diagnosed with “disabling or chronic migraine” without referring them to migraine specialists, with only 18% of GPs usually or always referring these patients to migraine specialists (Fig. 1). Referral rates differed between countries, ranging from 5% in France to 40% in Italy (\( p = 0.004 \) (Fig. 1).

Among those GPs who continued with the management of patients with CM without referring them to migraine specialists, 82% treated them with acute medication (analgesics, anti-emetics or specific anti-migraine medication), and 72% with preventive medication, when the frequency or intensity of the migraine episodes required it (Table 1). Of note, the proportion of GPs prescribing acute and preventive treatment differed significantly between countries (Table 1).

Regarding type of acute medication, GPs estimated that 59% of their patients with CM had been prescribed with analgesics and/or anti-emetics, and 55% with specific anti-migraine treatment (Table 1). Regarding preventive medication, 72% of the participants prescribed it when needed, and they estimated that 55% of their patients with CM were using preventive treatment (Table 1). Percentages of patients who had received analgesics/anti-emetics, specific symptomatic migraine treatment and/or preventive treatment were similar across countries (Table 1).

Anamnesis guide for the identification and management of CM: need and topics to be included.
Across countries, only 13% of GPs considered that they had received enough education on the management of patients with CM, and 39% responded that there was a lack of training (from 25% in UK to 55% in Italy, without statistically significant differences between countries).

On average, 95% of participants found that an anamnesis guide for patients with headache disorders should be
mandatory (23%) or would be helpful (72%) (Table 2). The perceived need for such a guide differed between countries ($p = 0.009$) but was overall high, from 88% in Germany to 100% in Spain (Table 2). Of note, GPs who were currently using an anamnesis guide found it significantly more useful than those who were not currently using it ($p = 0.017$).

More than 75% of participants considered mandatory the inclusion of the following topics in an anamnesis guide for migraine: pain characteristics, frequency of attacks, associated symptoms, treatments used and their efficacy, patient's age and trigger factors (Fig. 2). Some differences were found between countries in judging as

Table 1  Prescription patterns of GPs who do not refer patients with CM

|                                | TOTAL n = 164 | France n = 39 | Germany n = 34 | Italy n = 24 | Spain n = 33 | UK n = 34 | p value between countries |
|--------------------------------|---------------|---------------|----------------|--------------|--------------|-----------|--------------------------|
| **GPs who prescribe acute medication when needed, n (%)** |               |               |                |              |              |           |                          |
| % of my patients have been prescribed analgesics or anti-emetics*, mean (min, max) | 59% (0, 100) 58% (0, 100) | 61% (8, 100) 62% (15, 100) | 62% (10, 100) 49% (10, 100) | 49% (10, 100) | 61% (30, 90) | 0.521      |
| % of my patients have been prescribed anti-migraine acute treatment*, mean (min, max) | 55% (0, 100) 57% (10, 100) | 51% (0, 100) 57% (20, 100) | 52% (10, 100) 61% (30, 100) | 57% (20, 100) 61% (30, 90) | 61% (30, 90) | 0.625      |
| **GPs who prescribe preventive treatment when needed, n (%)** |               |               |                |              |              |           |                          |
| % of my patients are currently under preventive treatment* mean (min, max) | 55% (3, 100) 59% (3, 100) | 47% (5, 100) 53% (10, 100) | 48% (5, 100) 64% (20, 100) | 64% (20, 100) 64% (20, 100) | 64% (20, 100) | 0.108      |

* $p < 0.05$

Table 2  GPs views on need for anamnesis guide and patient diary for chronic migraine

|                                | TOTAL n = 201 | France n = 41 | Germany n = 40 | Italy n = 40 | Spain n = 40 | UK n = 40 | p value |
|--------------------------------|---------------|---------------|----------------|--------------|--------------|-----------|---------|
| **Need for anamnesis guide**   |               |               |                |              |              |           |         |
| Mandatory                      | 22.9%         | 22.0%         | 20.0%          | 22.5%        | 42.5%        | 7.5%      | 0.009*  |
| Helpful                        | 71.6%         | 70.7%         | 67.5%          | 75.0%        | 57.5%        | 87.5%     |
| Needless                       | 5.5%          | 7.3%          | 12.5%          | 2.5%         | 0.0%         | 5.0%      |
| **Need for a patient diary**   |               |               |                |              |              |           |         |
| Mandatory                      | 31.8%         | 24.4%         | 30.0%          | 32.5%        | 47.5%        | 25.0%     | 0.156   |
| Helpful                        | 65.2%         | 70.7%         | 62.5%          | 65.0%        | 52.5%        | 75.0%     |
| Needless                       | 3.0%          | 4.9%          | 7.5%           | 2.5%         | 0.0%         | 0.0%      |
| **Inclusion of red flags**     |               |               |                |              |              |           |         |
| Mandatory                      | 55.2%         | 51.2%         | 42.5%          | 25.0%        | 72.5%        | 85.0%     | < 0.001* |
| Helpful                        | 40.8%         | 48.8%         | 52.5%          | 62.5%        | 27.5%        | 12.5%     |
| Needless                       | 4.0%          | 0.0%          | 5.0%           | 12.5%        | 0.0%         | 2.5%      |
| **Inclusion of referral recommendations** |               |               |                |              |              |           |         |
| Mandatory                      | 30.8%         | 17.1%         | 17.5%          | 10.0%        | 72.5%        | 37.5%     | < 0.001* |
| Helpful                        | 58.7%         | 73.2%         | 60.0%          | 77.5%        | 25.0%        | 57.5%     |
| Needless                       | 10.4%         | 9.7%          | 22.5%          | 12.5%        | 2.5%         | 5.0%      |
| **Inclusion of a validated scale to measure impact of migraine on patient’s daily life** |               |               |                |              |              |           |         |
| Mandatory                      | 28.4%         | 24.4%         | 22.5%          | 20.0%        | 40.0%        | 35.0%     | 0.188   |
| Helpful                        | 65.2%         | 65.9%         | 65.0%          | 75.0%        | 55.0%        | 65.0%     |
| Needless                       | 6.5%          | 9.8%          | 12.5%          | 5.0%         | 5.0%         | 0.0%      |
| **Inclusion of a validated diagnostic tool** |               |               |                |              |              |           |         |
| Mandatory                      | 30.8%         | 36.6%         | 22.5%          | 7.5%         | 42.5%        | 45.0%     | 0.003*  |
| Helpful                        | 64.2%         | 61.0%         | 70.0%          | 80.0%        | 55.0%        | 55.0%     |
| Needless                       | 5.0%          | 2.4%          | 7.5%           | 12.5%        | 2.5%         | 0.0%      |

* $p < 0.05$
mandatory the inclusion of trigger factors (ranging from 60% in Italy to 93% in Spain, \( p = 0.008 \)), aggravating factors (from 48% in Italy to 85% in the UK, \( p = 0.006 \)) and patient background (from 40% in Italy to 88% in Spain, \( p = 0.004 \)) (Fig. 2).

The use of a patient diary was favoured by 97% of participants (considered “mandatory” or “helpful”), with no differences between countries (Table 2). Those GPs who did not normally use a patient diary in their clinical practice found it less important than those who regularly used it (\( p = 0.036 \)).

Regarding the topics that should be recorded in a patient diary, more than 75% of participants considered mandatory the inclusion of: headache attack duration, intensity and characteristics, number of headache days, and medications used and their efficacy (Fig. 3). Some differences were seen between countries (Fig. 3).

Regarding the inclusion of red flags/warning features in a migraine anamnesis guide, 96% of GPs found that their inclusion would be beneficial, with differences between countries in judging it mandatory: from 25% in Italy to 85% in the UK (\( p < 0.001 \)) (Table 2).

Fig. 2 Topics that need to be included in an anamnesis guide for chronic migraine. Legend: * \( p < 0.05 \)

Fig. 3 Topics that need to be included in the patient diary. Legend: * \( p < 0.05 \)
More than 90% of participants favoured the inclusion of referral recommendations, a validated diagnostic tool and a validated scale to measure the impact of migraine on patients’ daily life (Table 2). Differences were seen between countries as to whether recommendations should be considered mandatory, from 73% of GPs in Spain to only 10% in Italy (p < 0.001). Similarly, inclusion of a validated diagnostic tool was considered mandatory by 7.5% of Italian GPs, versus 42% of GPs in Spain and 45% in UK (Table 2).

Lastly, participants had different preferences regarding the format of the guide (checklist or short descriptive list, electronic or paper) (data not shown).

Discussion

Our results emphasize the need for guidance on the identification and management of patients with CM in family practice across Europe. While only 13% of GPs considered that they had received sufficient training on the management of CM, 82% did not refer patients to migraine specialists when CM was diagnosed, in contrast to guidelines recommendations. Among the GPs who proceeded with the management of patients with CM without referring, 82% prescribed acute treatment and 72% preventive treatment, when needed. Those GPs who did not refer after CM diagnosis estimated that 55% of their patients were currently receiving preventive treatment. As pointed out in the previously published results from this survey, CM treatments prescribed in the primary setting are not in accordance with local and international recommendations [21].

CM is complex and difficult to manage, as it involves not only more frequent migraine but is usually accompanied by different comorbidities and medication overuse [13]. According to European and local current guidelines, CM should be recognised and diagnosed in primary care, but mainly managed by a specialist [13, 22, 23]. Even though the recently updated “Aids to management of headache disorders in primary care” [13] includes a wide variety of tools to support GPs in the identification of CM, in this study, only 18% of GPs considered it necessary to refer their patients to migraine specialists when CM was diagnosed, supporting the need for improved guidance and continuing medical education in the primary care setting.

The assessment of headache disorders patients in the emergency department (ED) setting differs from the assessment in primary care, and a recent work aimed to analyse the different stages of the ED headache management to identify those deficiencies that can be overcome by a fast referral to a headache clinic [24]. The authors found that 75% of patients underwent head computed tomography, 19.3% received a neurological consultation, 43% did not receive any pharmacological treatment and 62.7% still had headache at discharge [24]. Furthermore, the concordance analysis showed a low agreement for the diagnosis between triage nurse, ED physicians and headache centre [24]. All these issues could be avoided if those patients had been correctly diagnosed in the primary care and referred to headache specialists when needed [24]. In this sense, the Spanish Society of Neurology’s Headache Study Group (GECSEN) has recently published a series of recommendations that aim to help ED and primary care physicians in the management of patients with headache and optimize their referral to specialists [25, 26]. Moreover, prescription of some preventive treatments for CM is restricted to migraine specialist care in most of the European countries [13]. The low referral rate reported by GPs in our study suggests a high percentage of undertreatment of patients with CM.

Several studies have shown that patients with CM are very commonly undertreated [16, 19, 27]. Suboptimal treatment is also observed in our study, with 55% of the patients with CM treated by GPs currently receiving preventive treatment. Preventive treatment is recommended in patients with uncontrolled migraine despite the use of acute medication, who experience frequent (4 or more) attacks per month [22]. Optimization of migraine treatment is important for prognosis and patients’ quality of life. Acute treatment failure cause more frequent attacks, which contribute to the risk of CM [28]. Transformation of a common episodic migraine into a chronic headache disorders is also associated with medication overuse [13], and a systematic review of case-controlled and longitudinal studies identified headache days frequency, depression and medication overuse/high-frequency use as risks factors for developing CM [20].

The differences observed among countries could be related to differences between healthcare systems dynamics, patient’s journey and availability of information on headache disorders management that is targeted to GPs. In the UK, the British Association for the Study of Headache (BASH) guidelines for the diagnosis and management of headache disorders include comprehensive information on CM management and are directed to all HCP [22]. In this sense, more GPs in the UK prescribed preventive treatment to patients with CM (94% in the UK compared to an average of 72% across countries) and less prescribed acute treatment (59% vs. 82%, respectively).

Despite being one of the most prevalent and disabling group of diseases, formal training on Headache Medicine is very limited [12, 29] and some knowledge gaps on management of headache disorders such as CM have been repeatedly reported in both family practice and specialist settings [15, 29–32]. In agreement with
this, only 13% of GPs considered that they had received enough education about management of CM.

In our project, 95% of GPs considered helpful or mandatory the use of an anamnesis guide for patients with headache disorders. Diagnosis and management of headache disorders can be challenging for non-expert physicians [10]. A comprehensive tool to help diagnose headache disorders, in particular chronic headache disorders, has been lacking [10]. Several tools to help in the identification of migraine and CM (e.g., ID-Migraine [33], ID-CM [34]) are available; however, the majority of them are self-administered questionnaires that do not include warning features, referral recommendations or tools to assess impact of migraine on patients’ lives [10]. In contrast, more than 90% of GPs in this survey considered helpful or mandatory the inclusion of these features in an anamnesis guide. The inclusion of red flags in a diagnostic tool is of high importance to help the differential diagnosis of any serious secondary headache disorders that requires specific treatment and/or referral [35]. In agreement with that, the majority of GPs in the survey considered useful their inclusion in an anamnesis guide.

Diagnosis of the most common headache disorders should be accurately done in primary care [13, 36]. A comprehensive tool that provides guidance for migraine anamnesis would reduce unnecessary referral of patients with episodic migraine and provide better care of patients with CM by speeding up referral and timely access to preventive treatment. The recent update of the “Aids to management of headache disorders in primary care” [13], contains a number of tools that have been requested by the GPs in this survey, such as a diagnosis guide of headache disorders including warning features, aids for management of CM, referral recommendations, and a headache diary and calendar.

This project has some limitations. It is based on a survey and therefore relies on respondents’ recall. Taking into consideration the inclusion criteria defined to participate in the survey, even if not headache specialists, the GPs’ experience of CM might have influenced the results and can limit their extrapolation to all primary care physicians. We did not include extensive medical information of the patients treated by GPs, and thus we could not evaluate severity of migraine or specific type of treatment received. Lastly, inclusion criteria to participate in the survey could create a certain bias in the results, as participants had some clinical experience with headache disorders. This may suggest that undertreatment of patients with CM in primary care could be higher than reported here.

Conclusions
Our results suggest that GPs would benefit from greater of application of management guidelines and continuing medical education on diagnosis and management of headache disorders, specifically CM. Better identification of patients with CM would ensure their better management, and optimal referral to migraine specialists when needed improving patient access to more effective preventive treatments.

The vast majority of GPs considered of great importance the use of an anamnesis guide for CM. Most of the features that GPs considered helpful or mandatory in our survey (i.e., a headache diary, red flags, referral recommendations, and a validated scale to assess impact of migraine on patients’ daily life) are included in the 2019 update of the “Aids to management of headache disorders in primary care” [13].

Abbreviations
BASH: British Association for the Study of Headache; CM: Chronic migraine; EM: Episodic migraine; ED: Emergency Department; EHF: European Headache Federation; GP: General practitioner; HCP: Healthcare practitioner; MOH: Medication-overuse headache; TTH: Tension-type headache.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12875-021-01402-2.

Acknowledgements
We thank the GPs that participated in this survey, to Maite Artés, Nathalie Bofarull and Malena Águila (Adelphi Targis S.L.) for the project management and contribution along the study, and to Alba Gomez and Alba Llopis for their medical writing assistance.

Authors’ contributions
All authors were involved in the writing and review of this article and meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). All authors read and approved the final manuscript.

Funding
Medical writing assistance and the page processing charges for this article have been financially supported by Novartis Pharma AG. The authors have received no payment to write this article.

Ethics Committee approval was not applicable in this survey because its objective was to understand chronic migraine patients’ management in the primary care setting. There was no need to collect any type of patient data or information, hence the approval of an Ethics Committee or patient informed consent was not required.

All survey participants gave their written consent.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate

Ethics Committee approval was not applicable in this survey because its objective was to understand chronic migraine patients’ management in the primary care setting. There was no need to collect any type of patient data or information, hence the approval of an Ethics Committee or patient informed consent was not required. All survey participants gave their written consent.

Consent for publication

Not applicable.

Competing interests

Dr. Guerrero reports personal fees from Novartis during the conduct of the study, and personal fees from Allergan, Exeltis, Eli Lilly and Teva outside the submitted work. Dr. Negro reports personal fees from Novartis during the conduct of the study, and personal fees from Allergan, Eli Lilly and Teva, outside the submitted work. Dr. Ryvlin reports personal fees from Novartis, during the conduct of the study and personal fees from Eli Lilly and Novartis outside the submitted work. Dr. Skorobogatykh reports personal fees from Novartis during the conduct of the study, and personal fees from Novartis and Teva, outside the submitted work. Dr. Rainel Sanchez-De la Rosa reports he is an employee and stakeholder of Novartis Pharma AG. Dr. Israel-Wilner has nothing to disclose. Dr. Sundal reports personal fees from Novartis, during the conduct of the study and personal fees from Allergan, outside the submitted work.

Dr. MacGregor reports personal fees from Novartis, during the conduct of the study, personal fees from Eli Lilly, outside the submitted work, and Co-author of Aids to management of headache disorders in primary care (2nd edition): On behalf of the European Headache Federation and Lifting the Burden: The Global Campaign against Headache. Vol 20, Journal of Headache and Pain. The Journal of Headache and Pain, 2019.

Author details

1 Neurology, Department, Headache Unit, Hospital ClinicoUniversitario, Valladolid, Spain. 2 Department of Medicine, University of Valladolid, Valladolid, Spain. 3 Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. 4 Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy. 5 Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy. 6 Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland. 7 University Headache Clinic, Moscow, Russia. 8 Region Europe Medical Department, Novartis Pharma AG, Basel, Switzerland. 9 Specialized Center of Neurology Berlin (NFZB), Berlin, Germany. 10 Department of Neurology, Neurocinic Norway, Lillestram, Norway. 11 Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 12 Earts Health NHS Trust, London, UK. 13 Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Queen Mary University of London, London, UK.

Received: 16 September 2020 Accepted: 23 February 2021 Published online: 20 March 2021

References

1. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–76.

2. Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, AFE, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (London, England). 2017;380(10010):1211–59.

3. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17. https://pubmed.ncbi.nlm.nih.gov/29468450.

4. Bigal ME, Serrano D, Reed ML, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559–66.

5. Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lamb C, Lantéri-Minet M, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15(1):1–11.

6. Manack AN, Buse DC, Lipton RB. Chronic migraine epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70–8.

7. Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, et al. Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59(8):1286–99.

8. Headache Classification Committee of the International Headache Society (IHS) Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202.

9. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.

10. Potter R, Probyn K, Bernstein C, Pincus T, Underwood M, Matharu M. Diagnostic and classification tools for chronic headache disorders: A systematic review. Cephalalgia. 2019;39(6):761–84.

11. Finley CR, Chan DS, Scott MBA, Crdp G. What are the most common conditions in primary care? Une vue systématique Les problèmes de santé les plus fréquents dans les soins primaires. Can Fam Physician. 2018;64:582–40.

12. WHO. Atlas of headache disorders and resources in the world. World Health Organ. 2011;72. http://www.who.int/mental_health/manag ement/atlas_ headache_disorders/en/.

13. Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, et al. Aids to management of headache disorders in primary care (2nd edition): On behalf of the European Headache Federation and Lifting the Burden: The Global Campaign against Headache. Vol 20, Journal of Headache and Pain. J Headache Pain. 2019;20(1):1–52.

14. MacGregor A. Migraine. Ann Intern Med. 2017;166(7):ITC49–64.

15. Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe – evidence from the Eurolight study. J Headache Pain. 2018;19(1):1–9.

16. Dodick DW, Loder EW, Manack Adams A, Buse DC, Fanning KM, Reed ML, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: Results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2016;56(5):821–34.

17. Viana M, Khaliq F, Zecca C, Figueroa MDL, Sances G, Di Piero V, et al. Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. Eur J Neurol. 2020;27(3):S36–41.

18. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157–68.

19. Young NP, Philpot LM, Vierkan RA, Rosedahl JK, Upadhyaya SG, Harris A, et al. Episodic and chronic migraine in primary care. Headache. 2019;59(7):1042–51.

20. Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: a systematic review. Headache. 2019;59(3):306–38.

21. Ryvlin P, Skorobogatykh K, Negro A, De La Rosa RS, Israel-Wilner H, Sundal C, et al. Current clinical practice in disabling and chronic migraine in the primary care setting: results from the European My-LIFE and treatment of migraine attacks and prevention of migraine: Guidelines by the German migraine and headache society and the German society of neurology. Céphalalgie. 2019;31(3):2514183X18823377.7. https://doi.org/10.1177/2514183X18823377.

22. British Association for the Study of Headache (BASH). BASH National Headache Management System for Adults [Internet]. 2019. Available from: http://www.bash.org.uk/guidelines/.

23. Diener H-C, Holle-Lee D, Nägel S, Dresler T, Gaul C, Göbel H, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: Results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2016;56(5):821–34.

24. Guerrero et al. BMC Fam Pract (2021) 22:54

25. Diener H-C, Holle-Lee D, Nägel S, Dresler T, Gaul C, Göbel H, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: Results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2016;56(5):821–34.
or Primary Care: Recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia. 2020;35(3):176–84.

26. Gago-Vega AB, Díaz de Terán J, González-García N, González-Oría C, González-Quintanilla V, Míguez-Olondo A, et al. How and when to refer patients diagnosed with secondary headache and other craniofacial pain in the Emergency Department and Primary Care: Recommendations of the Spanish Society of Neurology’s Headache Study Group. Neurologia. 2020;35(5):323–31.

27. Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache J Head Face Pain. 2013;53(1):81–92. https://doi.org/10.1111/j.1526-4610.2012.02265.x [cited 2020 Jun 2].

28. Xu J, Kong F, Buse DC. Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. Cephalalgia. 2020;40(5):503–16.

29. Dodick D, Edvinsson L, Makino T, Grisold W, Sakai F, Jensen R, et al. Vancouver declaration on global headache patient advocacy 2018. Cephalalgia. 2018;38(13):1899–909.

30. Minen MT, Robbins MS, Loder E, Nahas S, Gautreaux J, Litin S, et al. Addressing the crisis of diagnosis and management of migraine in primary care: a summary of the American Headache Society FrontLine Primary Care Advisory Board. Headache. 2020;60(5):1000–4.

31. Kristoffersen ES, Faiz KW, Winsvold BS. Neurology residents’ knowledge of the management of headache. Cephalalgia. 2019;39(11):1396–406.

32. Minen MT, Loder E, Tishler L, Silbersweig D. Migraine diagnosis and treatment: A knowledge and needs assessment among primary care providers. Cephalalgia. 2015;36(4):358–70.

33. Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, et al. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003;61(3):375–82.

34. Lipton RB, Serrano D, Buse DC, Pavlovic JM, Blumenfeld AM, Dodick DW, et al. Improving the detection of chronic migraine: development and validation of identify chronic migraine (ID-CM). Cephalalgia. 2016;36(3):203–15.

35. Do TP, Remmers A, Schytz HW, Schankin C, Nelson SE, Obermann M, et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology. 2019;92(5):134–44.

36. Steiner TJ, Antonaci F, Jensen R, Lainez NUA, Lanteri-Minet M, Valade D. Recommendations for headache service organisation and delivery in Europe: J Headache Pain. 2011;12(4):419–26.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.